We report a patient who developed a left-sided malignant teratoma with ipsilateral para-aortic nodes at the age of 20 years. Following treatment with left orchidectomy, abdominal and pelvic radiotherapy and chemotherapy, he was found to be azoospermic. More than 14 years after treatment, he regained his fertility. Similar prolonged iatrogenic depression of spermatogenesis has been reported in younger lymphoma patients; however, in post-pubertal patients with testicular tumour this has not been frequently reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0936-6555(05)80239-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of clinicopathological characteristics and prognosis between primary squamous cell carcinoma of the thyroid and squamous cell carcinoma combined with papillary thyroid carcinoma.
Front Endocrinol (Lausanne)
January 2025
Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Primary squamous cell carcinoma of the thyroid (PSCCT) has recently been reclassified as a morphologic pattern of anaplastic thyroid carcinoma (ATC). Consequently, PSCCT and squamous cell carcinoma with papillary thyroid carcinoma (SCC-PTC) were categorized as ATC. However, in terms of clinical characteristics and overall prognosis, whether PSCCT is similar to SCC-PTC has yet to be sufficiently investigated.
View Article and Find Full Text PDFSuppression of MCP-1, IFN-γ and IL-6 production of HNSCC by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival.
Front Immunol
January 2025
Department of Otorhinolaryngology, Head and Neck surgery, University Hospital Leipzig, Leipzig, Germany.
Background: Adding pembrolizumab, an anti-PD-1 antibody approved for treatment of head and neck squamous cell carcinoma (HNSCC) to neoadjuvant (induction-) chemotherapy utilizing docetaxel and cisplatin (TP) followed by radiotherapy may improve outcome in larynx organ-preservation (LOP) that is investigated in the European Larynx-Organ preservation Study (ELOS). As biomarkers for response to TP and pembrolizumab +TP are missing but may include cytokines, this work aims on determining cytokines potentially linked to outcome as prognostic markers sufficient to predict and/or monitor response to successful LOP.
Methods: Collagenase IV digests were generated from 47 histopathological confirmed HNSCC tumor samples and seeded in 96-well plates containing pembrolizumab, docetaxel, cisplatin either solely or in binary or ternary combination.
Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment.
J Pharm Anal
January 2025
School of Life Sciences, Chongqing University, Chongqing, 401331, China.
Gastrointestinal (GI) cancers are prevalent globally, with leading incidence and mortality rates among malignant tumors. Despite notable advancements in surgical resection, radiotherapy, and chemotherapy, the overall survival rates remain low. Hence, it is imperative to explore alternative approaches that enhance patient outcomes.
View Article and Find Full Text PDFRole of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases.
Hepat Oncol
December 2024
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis. Survival outcome was compared between groups with immunotherapy and groups without immunotherapy. Chemoimmunotherapy was associated with improved OS (hazard ratio [HR] 0.
View Article and Find Full Text PDFSurvival in elderly glioblastoma patients: The often overlooked role of radiotherapy and chemotherapy.
J Clin Neurosci
January 2025
Department of Biology Education Yayasan Potret Indonesia Sejahtera Langsa Indonesia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!